566 related articles for article (PubMed ID: 7671257)
1. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
4. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
[TBL] [Abstract][Full Text] [Related]
5. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Guo Y; Kyprianou N
Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
[TBL] [Abstract][Full Text] [Related]
6. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.
Burchardt T; Burchardt M; Chen MW; Cao Y; de la Taille A; Shabsigh A; Hayek O; Dorai T; Buttyan R
J Urol; 1999 Nov; 162(5):1800-5. PubMed ID: 10524938
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
8. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
9. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
10. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
11. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
12. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
[TBL] [Abstract][Full Text] [Related]
13. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
14. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer.
Rothermund CA; Kondrikov D; Lin MF; Vishwanatha JK
Prostate Cancer Prostatic Dis; 2002; 5(3):236-45. PubMed ID: 12496988
[TBL] [Abstract][Full Text] [Related]
15. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
Eder IE; Hoffmann J; Rogatsch H; Schäfer G; Zopf D; Bartsch G; Klocker H
Cancer Gene Ther; 2002 Feb; 9(2):117-25. PubMed ID: 11857028
[TBL] [Abstract][Full Text] [Related]
18. Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents.
Dorai T; Goluboff ET; Olsson CA; Buttyan R
Anticancer Res; 1997; 17(5A):3307-12. PubMed ID: 9413164
[TBL] [Abstract][Full Text] [Related]
19. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells.
Bruckheimer EM; Kyprianou N
Prostate; 2002 Oct; 53(2):133-42. PubMed ID: 12242728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
